Comar, Inc. Launches AccuCup(TM) - A Printed Dosage Cup for Use in General and Pediatr... ( BUENA N.J. Aug. 6 /- Comar Incorp...)

Comar, Inc. Launches AccuCup(TM) - A Printed Dosage Cup for Use in General and Pediatric Markets

Date:8/6/2008

BUENA, N.J., Aug. 6 /PRNewswire/ -- Comar Incorporated, a leading designer and manufacturer of precision liquid dispensing products and plastic packaging solutions for the pharmaceutical market, announced today that it has officially launched "AccuCup(TM)". AccuCup is the first commercially available dosage cup with measurement markings that are printed on the outside of the cup with cured and durable, FDA compliant, food grade inks. AccuCup is a stronger and safer alternative to embossed dosage cups, particularly in liquid-drug dispensing applications where "clearly visible accuracy" and synchronizing the packaging label instructions and brand with cup-print markings are important.

AccuCup(TM) is now being offered to the general and pediatric market with the flexibility to fit popular child-resistant closures from 22 to 24mm in diameter. Drug manufacturers and packagers now have an "affordable and quick option" to enable the printing of custom measurements, product brands and instructions in up to 2 colors, on the outside of a standard, physical blank- cup design. The customer will also have the added advantage of engaging Comar's Engineering Design Team to develop a "custom rib configuration" inside the AccuCup(TM) to fit unique cap designs. Additionally, AccuCup will be available in a "Stock-Standard Cup" design with generic markings of up to 20mL and 4 tsp.

According to Mike Ruggieri, President of Comar; "Our decision to offer AccuCup(TM) to the market was a proactive response to the pharmaceutical industry's and FDA's continuing concerns over the safety and effectiveness of selected OTC pediatric liquid cough and cold medications. Not only are we actively involved in the design of innovative packaging and dosing solutions for the pharmaceutical industry, but as involved members of the Consumer Healthcare Products Association/CHPA and IOPP, among other distinguished drug and packaging organizations, Comar is committed to raising the standard
'/>"/>

SOURCE Comar, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine news :

1. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
2. UPMC Health Plan Launches New Personal Health Record
3. HealthInsuranceFinders.com Launches Video Contest for Young Directors
4. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
5. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
6. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
7. Mannatech Launches Phase One of New Sales and Training Tools
8. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
9. Actavis Launches Carvedilol Tablets in the U.S.
10. MedQuist Re-launches New, Improved Web Site
11. Elsevier launches new journal: Stem Cell Research

Post Your Comments:

(Date:3/12/2010)... combines a focus on health and wellness and weight management ... , ... (Vocus) March 12, 2010 ... Natural Products Expo West today as part of the brand’s ... extension of the stage-one product portfolio, builds on the already ...

(Date:3/12/2010)... 1, 2010 new Medicare supplement (Medigap) plans M & N will ... never before seen with Medicare supplements. Precision Senior Marketing, a national ... for the new Medicare Supplement Plan N. , ... ... a national Medicare FMO, announced today that it is providing rates ...

(Date:3/12/2010)... ... , , ... ... ... A new grassroots campaign is expected to generate a million emails from constituents to their Congressional members, opposing ObamaCare. The One Million ...

(Date:3/12/2010)... of engineers from the CEIT-IK4 technological centre and doctors ... new tool for operating on the inner ear with ... auditory function during the surgery. This is the first ... implants, of which about a hundred are carried out ... new tool were four engineers from CEIT and five ...

(Date:3/12/2010)... ways to make your bedroom a place for ,rest and relaxation ... ... need sleep or how much sleep is recommended for optimal results. But ... decreased to the point where our health and well-being has been impaired. ... decreased productivity, drowsy driving and heart conditions. The people at ...

Breaking Medicine News(10 mins):Health News:Metabolife's New Green Tea + Vitamin D3 Helps Promote Bone Health and Supports Weight Management 2 Health News:Medicare Supplement Plan N Information and Rates Now Available Through Precision Senior Marketing 2 Health News:Think Tank & Radio Network Encourage Massive Resistance to ObamaCare 2 Health News:Think Tank & Radio Network Encourage Massive Resistance to ObamaCare 3 Health News:Think Tank & Radio Network Encourage Massive Resistance to ObamaCare 4 Health News:CEIT-IK4 designs tool for operations on people with severe or profound auditory loss 2 Health News:CEIT-IK4 designs tool for operations on people with severe or profound auditory loss 3 Health News:Tips to Create a Dreamy Bedroom to Improve Sleep 2 Health News:Tips to Create a Dreamy Bedroom to Improve Sleep 3

[0] Metabolife's New Green Tea + Vitamin D3 Helps Promote Bone Health and Supports Weight Management [0] Medicare Supplement Plan N Information and Rates Now Available Through Precision Senior Marketing [0] Think Tank & Radio Network Encourage Massive Resistance to ObamaCare [0] CEIT-IK4 designs tool for operations on people with severe or profound auditory loss [0] Tips to Create a Dreamy Bedroom to Improve Sleep

... Pistorius files appeal challenging International Association of Athletics Federation ... ... LONDON, Feb. 13 Oscar Pistorius -- a double amputee,athlete from ... today initiated an appeal before the Court of Arbitration for Sport,(CAS) ...

... 2008 The Elsevier Foundation has announced today that it ... institutions from around the world in support of initiatives that ... and medicine. The recipient programs were selected from over 150 ... the developing world and the academic workplace. , ...

... with glasses brought them up to snuff with ... News) -- Preschoolers with poor vision significantly improved ... wearing prescription glasses, a new study shows. , ... have early vision problems that are undiagnosed and ...

... a leading,provider of electronic payment solutions to the ... audit as a Payment Card,Industry (PCI) Level 1 ... are critical in an era when the Federal,Reserve ... 2/3rds,of all U.S. non-cash payments. The Payment Card ...

... ... - 85% Gross Profit ... Prior Year, CHICAGO, Feb. 13 The Female Health Company,(Amex: FHC ), which ... first quarter of,FY2008., For the three months ended December 31, 2007, the Company,s net,revenues ...

... for Continued Growth, CAMBRIDGE, Mass., Feb. 13 Genzyme Corporation,(Nasdaq: ... and,fourth quarter of 2007 and provided an outlook for continued strong ... revenue in 2007 increased 20 percent to $3.8 billion from $3.2 ... broadly driven by growth across all segments ...

Oscar Pistorius Aims to Compete on Level Playing Field at 2008 Beijing Olympics Elsevier Foundation announces grants for innovative libraries and new scholars Fixing Poor Vision Boosts Preschoolers' Test Scores Vanco Services Completes Annual Security Assessment The Female Health Company Reports 37% Revenue Growth and Record Profits for First Quarter of FY2008 Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year

(Date:3/11/2010)... -- With obesity in America reaching alarming levels -- across our adult and youth populations ... BodyMedia,s wearable body-monitoring technology either in conjunction with a group weight loss program or as ... more weight than individuals who attempted to battle the bulge solo. ... ... ...

(Date:3/11/2010)... The U.S. Food and Drug Administration ... drug application (sNDA) of a new six-month 45-mg ... Depot (leuprolide acetate for depot suspension) ... prostate cancer. Palliative treatment helps to relieve symptoms ... by suppressing the production of the hormone testosterone. ...

(Date:3/11/2010)... On March 10-11, 2010 , the Joint Advisory Committees ... and the Drug Safety and Risk Management Advisory Committees -- discussed the design ... SYMBICORT ® (budesonide/formoterol fumarate dihydrate). , ... ... ...

Breaking Medicine Technology:The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 2 The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 3 The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 4 The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 5 The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 6 Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 2 Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 3 Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 4 Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 5 Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 6 Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 7 AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma 2 AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma 3 AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma 4 AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma 5 AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma 6 AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma 7 AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma 8 Unraveling kidney cancer 64184 1 Unraveling kidney cancer 64184 2 Unraveling kidney cancer 64184 3 Canine compulsive disorder gene identified in dogs 11339 1 Canine compulsive disorder gene identified in dogs 11339 2 Canine compulsive disorder gene identified in dogs 11339 3 Team finds link between stomach cancer bug and cancer promoting factor 11334 1 Team finds link between stomach cancer bug and cancer promoting factor 11334 2 Team finds link between stomach cancer bug and cancer promoting factor 11334 3

[0] The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight [0] Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer [0] AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma

... SAN MATEO, Calif., June 10 /PRNewswire-FirstCall/ - NeurogesX, ... on developing and,commercializing novel pain management therapies, announced ... lead product candidate, NGX-4010, in the,journal Neurology. The ... Treatment of Painful HIV,Neuropathy," will appear in the ...

... a 24-week multi-center, randomized, open-label study presented ... ... Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) today announced data showing ... therapy for 24,weeks resulted in more patients achieving diabetes treatment goals ...

Other Medicine Technology:NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology 2 NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology 3 Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 2 Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 3 Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 4 Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 5

NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin

... (GH) is a monomeric protein produced and ... gland. GH is released from the pituitary ... under the regulatory control of hypothalamic somatostatin ... timing and frequency of GH release appears ...

... Cortisol is the most potent ... cortex. In plasma, most cortisol is ... globulin (CBG), with the remainder loosely ... specific intracellular receptors with effects in ...

... factor I (IGF-I or somatomedin C) is a ... It acts as a potent mitogen of cellular ... cell-surface receptors. In the circulation, IGF-I is bound ... the actions of IGF-I by modulating the interaction ...

... (PSA) derives its name from its first ... The majority of PSA circulates bound ... Serum concentrations of PSA are elevated in ... (BPH) and prostatitis [1-3]. In addition, PSA ...

Medicine Products:

hGH, Ultra-Sensitive ELISA Test Cortisol RIA Test IGF-I IRMA Test (Non-Extraction)Total PSA IRMA Test

Comar, Inc. Launches AccuCup(TM) - A Printed Dosage Cup for Use in General and Pediatr...( BUENA N.J. Aug. 6 /- Comar Incorp...),Health